Skip to main content

Articles

Page 17 of 38

  1. Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell...

    Authors: Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Min Wang and Jianxiang Wang
    Citation: Journal of Hematology & Oncology 2019 12:49
    Content type: Research Published on:

  2. The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using t...

    Authors: Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho and András Telekes
    Citation: Journal of Hematology & Oncology 2019 12:48
    Content type: Review Published on:

  3. Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembroliz...

    Authors: Sen Yang, Zhe Zhang and Qiming Wang
    Citation: Journal of Hematology & Oncology 2019 12:47
    Content type: Review Published on:

  4. PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agent...

    Authors: Yuanyuan Yang, Xiaolong Zhang, Fangzhen Lin, Mengshang Xiong, Dongmei Fan, Xiangfei Yuan, Yang Lu, Yuewen Song, Yizi Zhang, Mu Hao, Zhou Ye, Yanjun Zhang, Jianxiang Wang and Dongsheng Xiong
    Citation: Journal of Hematology & Oncology 2019 12:46
    Content type: Research Published on:

  5. Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing r...

    Authors: Chao Zhang, Natasha B. Leighl, Yi-Long Wu and Wen-Zhao Zhong
    Citation: Journal of Hematology & Oncology 2019 12:45
    Content type: Review Published on:

  6. Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with persistent disease.

    Authors: Francesco Saraceni, Myriam Labopin, Arne Brecht, Nicolaus Kröger, Matthias Eder, Johanna Tischer, Hélène Labussière-Wallet, Hermann Einsele, Dietrich Beelen, Donald Bunjes, Dietger Niederwieser, Tilmann Bochtler, Bipin N. Savani, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2019 12:44
    Content type: Research Published on:

  8. Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for severa...

    Authors: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery and Haitao Zhao
    Citation: Journal of Hematology & Oncology 2019 12:42
    Content type: Review Published on:

  9. Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the pas...

    Authors: Hongbing Ma, Iyer Swaminathan Padmanabhan, Simrit Parmar and Yuping Gong
    Citation: Journal of Hematology & Oncology 2019 12:41
    Content type: Review Published on:

  10. Successful treatment for acute myeloid leukemia (AML) remains challenging. Inhibiting immune checkpoint to enhance anti-tumor response is an attractive strategy for effective leukemia therapeutics. CD73 is a r...

    Authors: Yaxian Kong, Bei Jia, Chenchen Zhao, David F. Claxton, Arati Sharma, Charyguly Annageldiyev, Joseph S. Fotos, Hui Zeng, Robert F. Paulson, K. Sandeep Prabhu and Hong Zheng
    Citation: Journal of Hematology & Oncology 2019 12:40
    Content type: Research Published on:

  11. The Philadelphia (Ph) chromosome, resulting from the t(9;22)(q34;q11) translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of acute lymphoblastic leukemias (ALL). The deregulate...

    Authors: Simona Soverini, Renato Bassan and Thomas Lion
    Citation: Journal of Hematology & Oncology 2019 12:39
    Content type: Review Published on:

  12. Breast cancer is the most common malignancy in women all over the world. Genetic background of women contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase t...

    Authors: Zeinab Safarpour Lima, Mostafa Ghadamzadeh, Farzad Tahmasebi Arashloo, Ghazaleh Amjad, Mohammad Reza Ebadi and Ladan Younesi
    Citation: Journal of Hematology & Oncology 2019 12:38
    Content type: Review Published on:

  13. Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD73-expressing ...

    Authors: Xiao-Lu Ma, Min-Na Shen, Bo Hu, Bei-Li Wang, Wen-Jing Yang, Li-Hua Lv, Hao Wang, Yan Zhou, An-Li Jin, Yun-Fan Sun, Chuan-Yan Zhang, Shuang-Jian Qiu, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang…
    Citation: Journal of Hematology & Oncology 2019 12:37
    Content type: Research Published on:

  14. Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617...

    Authors: Claudia Schubert, Manuel Allhoff, Stefan Tillmann, Tiago Maié, Ivan G. Costa, Daniel B. Lipka, Mirle Schemionek, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, Nicolas Chatain and Steffen Koschmieder
    Citation: Journal of Hematology & Oncology 2019 12:36
    Content type: Research Published on:

  15. Extranodal NK/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with a dismal prognosis. Although l-asparaginase-based chemotherapy has resulted in improved response rates, relapse occurs in up to 5...

    Authors: Sanjay de Mel, Susan Swee-Shan Hue, Anand D. Jeyasekharan, Wee-Joo Chng and Siok-Bian Ng
    Citation: Journal of Hematology & Oncology 2019 12:33
    Content type: Review Published on:

  17. Ferroptosis is a novel type of cell death with distinct properties and recognizing functions involved in physical conditions or various diseases including cancers. The fast-growing studies of ferroptosis in ca...

    Authors: Yanhua Mou, Jun Wang, Jinchun Wu, Dan He, Chunfang Zhang, Chaojun Duan and Bin Li
    Citation: Journal of Hematology & Oncology 2019 12:34
    Content type: Review Published on:

  18. Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damaging response (DDR) has an established role in disease pathobiology. Indeed, a deregulation of DNA repair pathways may contr...

    Authors: Maria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, Caterina Riillo, Daniele Caracciolo, Francesca Scionti, Nicoletta Staropoli, Valeria Zuccalà, Lorenza Maltese, Anna Di Vito, Katia Grillone, Vito Barbieri, Mariamena Arbitrio, Maria Teresa Di Martino, Marco Rossi, Nicola Amodio…
    Citation: Journal of Hematology & Oncology 2019 12:32
    Content type: Research Published on:

  19. Myeloid-derived suppressor cells (MDSCs) are proposed to control graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the definition of human MDSCs has n...

    Authors: Ke Wang, Meng Lv, Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Su Zhao, Yuan-Yuan Zhang, Yu-Qian Sun, Zhi-Dong Wang, Pan Suo, Yang Zhou, Dan Liu, Shu-Zhen Zhai, Yan Hong, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu…
    Citation: Journal of Hematology & Oncology 2019 12:31
    Content type: Research Published on:

  20. Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsi...

    Authors: Marion Wobser, Alexandra Weber, Amelie Glunz, Saskia Tauch, Kristina Seitz, Tobias Butelmann, Sonja Hesbacher, Matthias Goebeler, René Bartz, Hella Kohlhof, David Schrama and Roland Houben
    Citation: Journal of Hematology & Oncology 2019 12:30
    Content type: Research Published on:

  21. Childhood medulloblastomas (MB) are heterogeneous and are divided into four molecular subgroups. The provisional non-wingless-activated (WNT)/non-sonic hedgehog-activated (SHH) category combining group 3 and g...

    Authors: Otília Menyhárt, Felice Giangaspero and Balázs Győrffy
    Citation: Journal of Hematology & Oncology 2019 12:29
    Content type: Review Published on:

  22. Natural killer T cell lymphoma (NKTL) is an aggressive disease with very poor treatment outcomes in the advanced stages. With chemotherapy, initial response rates to treatment are high but responses are short ...

    Authors: Nagavalli Somasundaram, Jing Quan Lim, Choon Kiat Ong and Soon Thye Lim
    Citation: Journal of Hematology & Oncology 2019 12:28
    Content type: Review Published on:

  23. Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, includin...

    Authors: Shuang Qin, Anping Li, Ming Yi, Shengnan Yu, Mingsheng Zhang and Kongming Wu
    Citation: Journal of Hematology & Oncology 2019 12:27
    Content type: Review Published on:

  24. Integrins are a family of transmembrane glycoprotein signaling receptors that can transmit bioinformation bidirectionally across the plasma membrane. Integrin αIIbβ3 is expressed at a high level in platelets a...

    Authors: Jiansong Huang, Xia Li, Xiaofeng Shi, Mark Zhu, Jinghan Wang, Shujuan Huang, Xin Huang, Huafeng Wang, Ling Li, Huan Deng, Yulan Zhou, Jianhua Mao, Zhangbiao Long, Zhixin Ma, Wenle Ye, Jiajia Pan…
    Citation: Journal of Hematology & Oncology 2019 12:26
    Content type: Review Published on:

  25. Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of...

    Authors: Liang Zhou, Yu Zhang, Yun Leng, Yun Dai, Maciej Kmieciak, Lora Kramer, Kanika Sharma, Yan Wang, William Craun and Steven Grant
    Citation: Journal of Hematology & Oncology 2019 12:25
    Content type: Research Published on:

  26. The original article [1] contains two errors in the MRD Testing sub-section of the Methods:

    Authors: Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:24
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:87

  27. The expression of CYP4Z1 and the pseudogene CYP4Z2P has been shown to be specifically increased in breast cancer by our group and others. Additionally, we previously revealed the roles of the competitive endog...

    Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li and Tao Xi
    Citation: Journal of Hematology & Oncology 2019 12:23
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:109

  28. There is a dearth of accurate information about patterns of mortality of lymphoid neoplasms and temporal trends in China. In this nationwide mortality study, we aimed to assess the mortality of lymphoma and my...

    Authors: Weiping Liu, Jiangmei Liu, Yuqin Song, Xiaopei Wang, Maigeng Zhou, Lijun Wang, Jun Ma and Jun Zhu
    Citation: Journal of Hematology & Oncology 2019 12:22
    Content type: Research Published on:

  29. Ring finger proteins (RNFs) were involved in carcinogenesis. Here, we aimed to explore the detailed mechanism of RNF128 in the progression of melanoma.

    Authors: Chuan-Yuan Wei, Meng-Xuan Zhu, Yan-Wen Yang, Peng-Fei Zhang, Xuan Yang, Rui Peng, Chao Gao, Jia-Cheng Lu, Lu Wang, Xin-Yi Deng, Nan-Hang Lu, Fa-Zhi Qi and Jian-Ying Gu
    Citation: Journal of Hematology & Oncology 2019 12:21
    Content type: Research Published on:

  30. Tumor microenvironment (TME) is a complex environment containing tumor cells, tumor-associated macrophages (TAMs), interstitial cells, and non-cellular components. Epithelial–mesenchymal transition (EMT), as a...

    Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu and Bin Xiong
    Citation: Journal of Hematology & Oncology 2019 12:20
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:122

  31. Increasing evidence has demonstrated that mesenchymal stem cells (MSCs) play a role in the construction of tumor microenvironments. Co-culture between tumor cells and MSCs provides an easy and useful platform ...

    Authors: Jing Li, Yajing Hao, Wenzhe Mao, Xiaowei Xue, Pengchao Xu, Lihui Liu, Jiao Yuan, Dongdong Zhang, Na Li, Hua Chen, Lin Zhao, Zhao Sun, Jianjun Luo, Runsheng Chen and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2019 12:19
    Content type: Research Published on:

  32. Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen recept...

    Authors: Jiang Lv, Ruocong Zhao, Di Wu, Diwei Zheng, Zhiping Wu, Jingxuan Shi, Xinru Wei, Qiting Wu, Youguo Long, Simiao Lin, Suna Wang, Zhi Wang, Yang Li, Yantao Chen, Qing He, Suimin Chen…
    Citation: Journal of Hematology & Oncology 2019 12:18
    Content type: Research Published on:

  33. The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or rela...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2019 12:17
    Content type: Review Published on:

  34. The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, t...

    Authors: Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu, Zhenghang Wang, Shu Zheng, Desen Wan, Jie He, Jianping Wang, Yi Ba, Chunmei Bai, Li Bai, Wei Bai, Feng Bi, Kaican Cai…
    Citation: Journal of Hematology & Oncology 2019 12:16
    Content type: Review Published on:

  35. The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual...

    Authors: Delong Liu, Juanjuan Zhao, Yongping Song, Xiaofeng Luo and Ting Yang
    Citation: Journal of Hematology & Oncology 2019 12:15
    Content type: Review Published on:

  36. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks effective therapeutic targets. Sperm-associated antigen 5 (SPAG5) is a mitotic spindle-associated protein that is involved...

    Authors: Ming Li, Anqi Li, Shuling Zhou, Hong Lv and Wentao Yang
    Citation: Journal of Hematology & Oncology 2019 12:14
    Content type: Research Published on:

  37. Allogeneic hematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adopt...

    Authors: Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke, Semjon Willier and Tobias Feuchtinger
    Citation: Journal of Hematology & Oncology 2019 12:13
    Content type: Review Published on:

  38. Adenylate kinase 4 (AK4) has been identified as a biomarker of metastasis in lung cancer. However, the impacts of AK4 on metabolic genes and its translational value for drug repositioning remain unclear.

    Authors: Yi-Hua Jan, Tsung-Ching Lai, Chih-Jen Yang, Yuan-Feng Lin, Ming-Shyan Huang and Michael Hsiao
    Citation: Journal of Hematology & Oncology 2019 12:12
    Content type: Research Published on:

  39. Leiomyosarcoma (LMS) is one of the most frequent soft tissue sarcoma subtypes and is characterized by a consistent deregulation of the PI3K/mTOR pathway. Cancer stem cells (CSCs) have been poorly studied in so...

    Authors: Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2019 12:11
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:116

  40. Cell-cell interactions maintain tissue homeostasis and contribute to dynamic alteration of the tumor microenvironment (TME). Communication between cancer and host cells not only promotes advanced disease aggre...

    Authors: Wei-Lun Hwang, Hsin-Yi Lan, Wei-Chung Cheng, Shih-Ching Huang and Muh-Hwa Yang
    Citation: Journal of Hematology & Oncology 2019 12:10
    Content type: Research Published on:

  41. Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chroni...

    Authors: Yongkun Sun, Lin Yang, Xuezhi Hao, Yutao Liu, Jinwen Zhang, Zhiqiang Ning and Yuankai Shi
    Citation: Journal of Hematology & Oncology 2019 12:9
    Content type: Research Published on:

  42. Long non-coding RNAs (lncRNAs) have emerged as a novel class of RNA due to its diverse mechanism in cancer development and progression. However, the role and expression pattern of lncRNAs in molecular subtypes...

    Authors: Alva Rani James, Michael P. Schroeder, Martin Neumann, Lorenz Bastian, Cornelia Eckert, Nicola Gökbuget, Jutta Ortiz Tanchez, Cornelia Schlee, Konstandina Isaakidis, Stefan Schwartz, Thomas Burmeister, Arend von Stackelberg, Michael A. Rieger, Stefanie Göllner, Martin Horstman, Martin Schrappe…
    Citation: Journal of Hematology & Oncology 2019 12:8
    Content type: Research Published on:

  43. JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I stud...

    Authors: Bixia Tang, Xieqiao Yan, Xinan Sheng, Lu Si, Chuanliang Cui, Yan Kong, Lili Mao, Bin Lian, Xue Bai, Xuan Wang, Siming Li, Li Zhou, Jiayi Yu, Jie Dai, Kai Wang, Jinwei Hu…
    Citation: Journal of Hematology & Oncology 2019 12:7
    Content type: Research Published on:

  44. There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outc...

    Authors: Narendranath Epperla, Kwang W. Ahn, Carlos Litovich, Sairah Ahmed, Minoo Battiwalla, Jonathon B. Cohen, Parastoo Dahi, Nosha Farhadfar, Umar Farooq, Cesar O. Freytes, Nilanjan Ghosh, Bradley Haverkos, Alex Herrera, Mark Hertzberg, Gerhard Hildebrandt, David Inwards…
    Citation: Journal of Hematology & Oncology 2019 12:6
    Content type: Research Published on:

  46. Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatme...

    Authors: Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Martino, Alessandra Larocca, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea…
    Citation: Journal of Hematology & Oncology 2019 12:4
    Content type: Research Published on:

  47. Abnormal expression of long non-coding RNAs (lncRNAs) has been found in almost all human tumors, providing numerous potential diagnostic biomarkers, prognostic biomarkers, and therapeutic targets.

    Authors: Mu Xu, Xiaoxiang Chen, Kang Lin, Kaixuan Zeng, Xiangxiang Liu, Xueni Xu, Bei Pan, Tao Xu, Li Sun, Bangshun He, Yuqin Pan, Huiling Sun and Shukui Wang
    Citation: Journal of Hematology & Oncology 2019 12:3
    Content type: Research Published on:

  48. Multiple myeloma (MM) is a clonal plasma cell malignancy associated with osteolytic bone disease. Recently, the role of MM-derived exosomes in the osteoclastogenesis has been demonstrated although the underlyi...

    Authors: Stefania Raimondo, Laura Saieva, Emanuela Vicario, Marzia Pucci, Denise Toscani, Mauro Manno, Samuele Raccosta, Nicola Giuliani and Riccardo Alessandro
    Citation: Journal of Hematology & Oncology 2019 12:2
    Content type: Research Published on:

  49. Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly s...

    Authors: Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour…
    Citation: Journal of Hematology & Oncology 2019 12:1
    Content type: Research Published on:

  50. Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistan...

    Authors: Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot and Carlo Gambacorti-Passerini
    Citation: Journal of Hematology & Oncology 2018 11:143
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us